Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 471

Sort by

Sort Order Select

Journal Articles

Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma

Blood (2021) 137 (23): 3272–3276.

https://doi.org/10.1182/blood.2020008865

Published: 2021

Includes: Supplemental data

Journal Articles

Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma

Blood (2021) 137 (19): 2621–2633.

https://doi.org/10.1182/blood.2020007445

Published: 2021

Includes: Supplemental data

Journal Articles

CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma

Blood (2021) 137 (17): 2321–2325.

https://doi.org/10.1182/blood.2020009432

Published: 2021

Includes: Supplemental data

Journal Articles

CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapy

Fraser Soares, Branson Chen, Jong Bok Lee, Musaddeque Ahmed, Dalam Ly, Enoch Tin, Hyeonjeong Kang, Yong Zeng, Nayeema Akhtar, Mark D. Minden, Housheng Hansen He, Li Zhang

Blood (2021) 137 (16): 2171–2181.

https://doi.org/10.1182/blood.2019004108

Published: 2021

Includes: Supplemental data

Journal Articles

How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy

Ibrahim Aldoss, Stephen J. Forman

Blood (2020) 135 (11): 804–813.

https://doi.org/10.1182/blood.2019002132

Published: 2020

Journal Articles

Virus-specific T-cell therapies for patients with primary immune deficiency

Michael D. Keller, Catherine M. Bollard

Blood (2020) 135 (9): 620–628.

https://doi.org/10.1182/blood.2019000924

Published: 2020

Journal Articles

Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity

Olli Dufva, Jan Koski, Pilvi Maliniemi, Aleksandr Ianevski, Jay Klievink, Judith Leitner, Petri Pölönen, Helena Hohtari, Khalid Saeed, Tiina Hannunen, Pekka Ellonen, Peter Steinberger, Matti Kankainen, Tero Aittokallio, Mikko A. I. Keränen, Matti Korhonen, Satu Mustjoki

Blood (2020) 135 (9): 597–609.

https://doi.org/10.1182/blood.2019002121

Published: 2020

Includes: Supplemental data

Journal Articles

Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL

Jing Pan, Shiyu Zuo, Biping Deng, Xiuwen Xu, Chuo Li, Qinlong Zheng, Zhuojun Ling, Weiliang Song, Jinlong Xu, Jiajia Duan, Zelin Wang, Xinjian Yu, Alex H. Chang, Xiaoming Feng, Chunrong Tong

Blood (2020) 135 (5): 387–391.

https://doi.org/10.1182/blood.2019003293

Published: 2020

Includes: Supplemental data

Journal Articles

Preclinical Evaluation of ALLO-819, an Allogeneic CAR T Cell Therapy Targeting FLT3 for the Treatment of Acute Myeloid Leukemia

Cesar Sommer, PhD, Hsin-Yuan Cheng, PhD, Yik Andy Yeung, PhD, Duy Nguyen, Janette Sutton, Zea Melton, Julien Valton, PhD, Kris Poulsen, Ivana Djuretic, PhD, Thomas Van Blarcom, PhD, Javier Chaparro-Riggers, PhD, Barbra Sasu, PhD

Blood (2019) 134 (Supplement_1): 3921.

https://doi.org/10.1182/blood-2019-129025

Published: 2019

Journal Articles

Resistance to Axicabtagene Ciloleucel Therapy in T Cell/Histiocyte-Rich Large B Cell Lymphoma

Jonathan Trujillo, MD PhD, James Godfrey, MD, Michael R. Bishop, MD, Peter A. Riedell, MD, Justin Kline, MD

Blood (2019) 134 (Supplement_1): 5238.

https://doi.org/10.1182/blood-2019-131941

Published: 2019

Journal Articles

Case Report: Sustained Remission Achieved from Anti-CD19 CAR T Cell Therapy Despite Prior Treatment with Anti-CD19 Antibody Tafasitamab (MOR208) in a Patient with Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Caspian Oliai, MD, Sven de Vos, MD PhD

Blood (2019) 134 (Supplement_1): 5360.

https://doi.org/10.1182/blood-2019-129371

Published: 2019

Journal Articles

Baseline Hypoalbuminemia Does Not Appear to be an Adverse Prognostic Factor in Patients with Relapse/Refractory B-Cell Lymphomas Treated with Axicabtagene Ciloleucel (axi-cel)

Blood (2019) 134 (Supplement_1): 5343.

https://doi.org/10.1182/blood-2019-126594

Published: 2019

Journal Articles

A Novel Revcar Platform for Switchable and Gated Tumor Targeting

Anja Feldmann, PhD, Anja Hoffmann, Enrico Kittel-Boselli, Ralf Bergmann, PhD, Stefanie Koristka, PhD, Nicole Berndt, PhD, Claudia Arndt, PhD, Liliana Raquel Loureiro, PhD, Nicola Mitwasi, Justyna Jureczek, Martin Bornhaeuser, MD, Michael Bachmann, MD

Blood (2019) 134 (Supplement_1): 5611.

https://doi.org/10.1182/blood-2019-128436

Published: 2019

Journal Articles

Coexistence of a Huge Venous Thromboembolism and Bleeding Tendency in Cytokine Release Syndrome during CAR-T Therapy

Haiyan Liu, MD, Ye Yang, PhD, Hongming Huang, MD

Blood (2019) 134 (Supplement_1): 5590.

https://doi.org/10.1182/blood-2019-129389

Published: 2019

Journal Articles

Evolving Data on CAR T-Cell Therapy for Multiple Myeloma, Novel Targets, Conditioning Regimens and Novel Constructs: A Systematic Review

Yusra Shao, MD, Daniel S Carlson, DO, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5547.

https://doi.org/10.1182/blood-2019-122292

Published: 2019

Journal Articles

The Effect of Apoptosis Inhibitor Blockade Agents on the Third Generation CD19 CAR T Cells

Mingya Yang, MD, Lei Wang, MD, Ming Ni, Maria-Luisa Schubert, MD, Brigitte Neuber, Angela Hückelhoven-Krauss, Ruben A. Gößmann, Christian Kleist, Volker Eckstein, Carsten Müller-Tidow, MD, Peter Dreger, Michael Schmitt, MD, Anita Schmitt, MD

Blood (2019) 134 (Supplement_1): 5620.

https://doi.org/10.1182/blood-2019-125622

Published: 2019

Journal Articles

Development of Novel Anti-CD10 Target Modules for Redirection of Universal CAR T Cells Against CD10-Positive Malignancies

Anja Feldmann, PhD, Stefanie Koristka, PhD, Claudia Arndt, PhD, Liliana Raquel Loureiro, PhD, Ralf Bergmann, PhD, Nicole Berndt, PhD, Anja Hoffmann, Justyna Jureczek, Nicola Mitwasi, Martin Bornhaeuser, MD, Václav Hořejší, Michael Bachmann, MD

Blood (2019) 134 (Supplement_1): 5612.

https://doi.org/10.1182/blood-2019-128193

Published: 2019

Journal Articles

Development of Target Modules for Early and Late Stage Cancer Treatment Using Switchable Unicar T Cell Therapy

Liliana Raquel Loureiro, PhD, Anja Feldmann, PhD, Ralf Bergmann, PhD, Nicole Berndt, PhD, Stefanie Koristka, PhD, Nicola Mitwasi, Anja Hoffmann, Justyna Jureczek, Martin Bornhaeuser, MD, Michael Bachmann, MD, Claudia Arndt, PhD

Blood (2019) 134 (Supplement_1): 5613.

https://doi.org/10.1182/blood-2019-128249

Published: 2019

Journal Articles

Targeting the FMS-like Tyrosin Kinase 3 with the Unicar System: Preclinical Comparison of Murine and Humanized Single-Chain Variable Fragment-Based Targeting Modules

Frederick Fasslrinner, MD, Claudia Arndt, PhD, Anja Feldmann, PhD, Stefanie Koristka, PhD, Liliana Raquel Loureiro, PhD, Marc Schmitz, MD, Gundram Jung, MD, Martin Bornhaeuser, MD, Michael Bachmann, MD

Blood (2019) 134 (Supplement_1): 5614.

https://doi.org/10.1182/blood-2019-124279

Published: 2019

Journal Articles

Updates in Clinical Data on FDA Fast Track Drugs for Relapsed Refractory Multiple Myeloma: A Systematic Review of Literature

Muhammad Abdullah Yousaf, MBBS, MD, Muhaddis Ejaz Ahmad, MD, Maaz Ahmed Yusufi, MD, Asim Tameez ud din, MD, Muhammad Qudrat Ullah, MD, Muhammad Yasir Anwar, MD, Abdul Rafae, MD, Mustafa Nadeem Malik, MD, Zunairah Shah, MBBS, Ahmed Ibrahim, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5579.

https://doi.org/10.1182/blood-2019-123296

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma

Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma

CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma

CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapy

How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy

Virus-specific T-cell therapies for patients with primary immune deficiency

Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity

Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL

Preclinical Evaluation of ALLO-819, an Allogeneic CAR T Cell Therapy Targeting FLT3 for the Treatment of Acute Myeloid Leukemia

Resistance to Axicabtagene Ciloleucel Therapy in T Cell/Histiocyte-Rich Large B Cell Lymphoma

Case Report: Sustained Remission Achieved from Anti-CD19 CAR T Cell Therapy Despite Prior Treatment with Anti-CD19 Antibody Tafasitamab (MOR208) in a Patient with Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Baseline Hypoalbuminemia Does Not Appear to be an Adverse Prognostic Factor in Patients with Relapse/Refractory B-Cell Lymphomas Treated with Axicabtagene Ciloleucel (axi-cel)

A Novel Revcar Platform for Switchable and Gated Tumor Targeting

Coexistence of a Huge Venous Thromboembolism and Bleeding Tendency in Cytokine Release Syndrome during CAR-T Therapy

Evolving Data on CAR T-Cell Therapy for Multiple Myeloma, Novel Targets, Conditioning Regimens and Novel Constructs: A Systematic Review

The Effect of Apoptosis Inhibitor Blockade Agents on the Third Generation CD19 CAR T Cells

Development of Novel Anti-CD10 Target Modules for Redirection of Universal CAR T Cells Against CD10-Positive Malignancies

Development of Target Modules for Early and Late Stage Cancer Treatment Using Switchable Unicar T Cell Therapy

Targeting the FMS-like Tyrosin Kinase 3 with the Unicar System: Preclinical Comparison of Murine and Humanized Single-Chain Variable Fragment-Based Targeting Modules

Updates in Clinical Data on FDA Fast Track Drugs for Relapsed Refractory Multiple Myeloma: A Systematic Review of Literature

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only